Drug intelligence / Profile preview

artemether + lumefantrine + hydroxyurea

Development stage: Preclinical
Lead developer: Academy of Military Medical Sciences
Modality: Small Molecules
Administration: Oral

Overview

This is not a single formulated drug product but rather represents the concurrent use of artemether-lumefantrine (an antimalarial combination) and hydroxyurea (a medication for sickle cell disease) in patients who have sickle cell disease and develop malaria. Artemether-lumefantrine is used to treat acute uncomplicated malaria by killing the organisms that cause the infection, while hydroxyurea is used in the management of sickle cell disease. Studies have investigated the safety and efficacy of using these medications together in patients with sickle cell disease who develop malaria infections.

Targets

RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on artemether + lumefantrine + hydroxyurea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on artemether + lumefantrine + hydroxyurea.

Explore the full profile